• By ICR Secretariat
  • Posted Thursday, May 19, 2022

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class


  • A drug combination including Roche’s experimental immunotherapy tiragolumab failed one of two main goals in a Phase 3 trial in a common form of lung cancer, a setback that casts doubt on the potential of a closely watched group of medicines aimed at a cellular target called TIGIT.